Takeda Pharmaceutical Company Limited (4502) Earnings Call Transcripts
Takeda Pharmaceutical Company Limited's Latest Earnings Call - March 29, 2026
Takeda Pharmaceutical Company Limited's earnings call for Q1 FY2026 highlighted significant developments in their pipeline, particularly the Phase III results for zasocitinib, a TYK2 inhibitor for psoriasis. Management emphasized the drug's potential to transform the psoriasis treatment landscape with its rapid and durable efficacy. Revenue and earnings figures were not disclosed, nor were any changes to financial guidance. However, the focus on upcoming drug launches, including zasocitinib, oveporexton, and rusfertide, signals potential revenue growth.
Reported metrics
| Metric | Value |
|---|---|
| sPGA 0/1 Achievement | 71% in Study 3001, 69% in Study 3002 (beat) |
| PASI 75 Achievement | 76% in Study 3001, 71% in Study 3002 (beat) |
| Clear Skin (PASI 100) | 42% of patients (beat) |
| DLQI Improvement | 60% of patients reported DLQI 0/1 (positive) |
Guidance from management
Takeda is on track to launch zasocitinib in the first half of 2027, with U.S. filing planned for this year. The company anticipates significant growth in the oral psoriasis market.
What management said
Thank you for the questions, Muraoka-san. For the first one in regard to the differences between zaso and other options that are available. I will ask Chinwe to address that. But let me start by saying, in general, it is challenging to make cross-trial comparisons, but Chinwe can provide some of his perspectives on how we view zaso in particular. For your second question, in terms of being second to launch, behind ic...
So thank you for the questions, Yamaguchi-san and [Foreign Language], I'm also in Tokyo. So unfortunately, I'm not with the team at AAD, but both Chinwe and Rhonda were there. So I will ask them to provide commentary on the atmosphere and the reception that we had for zasocitinib. And then in regard to your second question about our commercial assumptions, I will ask Rhonda to address that question. So Chinwe, do you...
What analysts pressed on
Analysts questioned the competitive positioning of zasocitinib against existing oral treatments, particularly icotrokinra, and the potential market share given the one-year delay in launch. Concerns were also raised about the higher-than-expected placebo response rates in clinical trials.
Main topics on the call
- Zasocitinib Phase III Results — Zasocitinib demonstrated significant efficacy in psoriasis, with 71% and 69% of patients achieving sPGA 0/1 in studies 3001 and 3002, respectively. Management stated, 'Zasocitinib is poised to be a leading oral treatment...
- Pipeline Developments — Takeda is preparing for the launch of three major drugs: zasocitinib, oveporexton, and rusfertide, all of which have shown promising Phase III results. Oveporexton and rusfertide have been granted priority review by the ...
- Market Positioning — Management highlighted the unmet need for effective oral psoriasis treatments, projecting the oral market to triple in the next decade. Zasocitinib's convenience as a once-daily pill with no fasting restrictions is a key...
- Safety Profile — The safety profile of zasocitinib was consistent with previous studies, with no new safety signals. Most adverse events were mild to moderate, primarily respiratory infections and acne.
Read the full Takeda Pharmaceutical Company Limited transcript (March 29, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (4502) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on TSE and is based in JP. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 64 calls on record spanning January 15, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 64 Takeda Pharmaceutical Company Limited earnings call transcripts on record, spanning January 15, 2020 to July 30, 2026. Based on this history, Takeda Pharmaceutical Company Limited reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- 4502
- Exchange
- TSE
- Country
- JP
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 64
- First call
- January 15, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly